Laboratory enhanced surveillance for meningococcal disease in Victoria
- PMID: 11885736
- DOI: 10.1046/j.1440-1754.2001.00678.x
Laboratory enhanced surveillance for meningococcal disease in Victoria
Abstract
Objective: To describe the epidemiological and microbiological characteristics and notification patterns of invasive meningococcal disease (IMD) in Victoria between 1990 and 1999.
Methods: Cases of IMD occurring between 1990 and 1995 identified in any of three databases were combined, matching where possible. Statistical modelling provided estimates of cases missing from all datasets. Notification sources for 1999 and 2000 cases were identified. Cases identified from notification and laboratory results provided the data to describe IMD epidemiology between 1990 and 1999.
Results: Between 1990 and 1995, 479 cases of IMD were identified. Three individual datasets each identified between 62 and 82% of cases and 47% of cases were identified in all three datasets. Statistical modelling estimated that between 37 and 83 additional cases were not identified by any dataset. Serogroup B and C strains caused 63 and 33% of culture-positive cases, respectively, with a substantial rise in serogroup C cases in 1999. Epidemiological characteristics remained relatively constant between 1990 and 1998, but an increase in patient age was seen in cases with serogroup C disease in 1999. In addition to three clonal strains seen elsewhere, an additional strain was identified that was unique to Victoria. Since January 1999, only 72% of notifications have come from treating doctors.
Conclusions: Meningococcal disease is of increasing public health significance in Victoria. Laboratory enhanced notification has improved case identification and detailed microbiological information has improved our understanding of the changing epidemiology of this disease. Collaboration with laboratories and other agencies, active investigation of putative cases and microbiological monitoring are important elements in supporting public health decisions about the control of IMD.
Comment in
-
Meningococcal vaccines: advances but new questions?J Paediatr Child Health. 2001 Oct;37(5):S1-2. doi: 10.1046/j.1440-1754.2001.00733.x. J Paediatr Child Health. 2001. PMID: 11885730 No abstract available.
Similar articles
-
Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004-2016.BMC Infect Dis. 2019 Oct 17;19(1):860. doi: 10.1186/s12879-019-4513-2. BMC Infect Dis. 2019. PMID: 31623567 Free PMC article.
-
Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.Vaccine. 2015 Oct 13;33(42):5678-5683. doi: 10.1016/j.vaccine.2015.08.023. Epub 2015 Aug 20. Vaccine. 2015. PMID: 26299749
-
National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001.Epidemiol Infect. 2002 Dec;129(3):459-70. doi: 10.1017/s0950268802007549. Epidemiol Infect. 2002. PMID: 12558328 Free PMC article.
-
Epidemiological burden of meningococcal disease in Brazil: A systematic literature review and database analysis.Int J Infect Dis. 2019 Mar;80:137-146. doi: 10.1016/j.ijid.2019.01.009. Epub 2019 Jan 11. Int J Infect Dis. 2019. PMID: 30641200
-
Global epidemiology of meningococcal disease.Vaccine. 2009 Jun 24;27 Suppl 2:B51-63. doi: 10.1016/j.vaccine.2009.04.063. Epub 2009 May 27. Vaccine. 2009. PMID: 19477562 Review.
Cited by
-
Using linked birth, notification, hospital and mortality data to examine false-positive meningococcal disease reporting and adjust disease incidence estimates for children in New South Wales, Australia.Epidemiol Infect. 2015 Sep;143(12):2570-9. doi: 10.1017/S0950268814003355. Epub 2015 Jan 9. Epidemiol Infect. 2015. PMID: 25573266 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical